S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,051.41 (-0.21%)
DOW   37,798.97 (+0.17%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Price, News & Analysis

$6.98
+0.57 (+8.89%)
(As of 04:00 PM ET)
Today's Range
$6.38
$7.06
50-Day Range
$6.41
$11.00
52-Week Range
$6.20
$18.65
Volume
66,215 shs
Average Volume
101,378 shs
Market Capitalization
$124.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Nuvectis Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
215.3% Upside
$21.00 Price Target
Short Interest
Bearish
12.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.33mentions of Nuvectis Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$51,450 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.52) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

524th out of 930 stocks

Pharmaceutical Preparations Industry

243rd out of 428 stocks

NVCT stock logo

About Nuvectis Pharma Stock (NASDAQ:NVCT)

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

NVCT Stock Price History

NVCT Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Nuvectis Pharma (NASDAQ:NVCT) Shares Down 1.5%
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
5 Healthcare Stocks to Buy for 2024
Nuvectis Pharma Inc NVCT
Nuvectis Pharma GAAP EPS of -$0.37
Recap: Nuvectis Pharma Q3 Earnings
See More Headlines
Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/16/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NVCT
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+215.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.70 per share

Miscellaneous

Free Float
10,866,000
Market Cap
$118.35 million
Optionable
Not Optionable
Beta
0.28
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Ron Bentsur M.B.A. (Age 58)
    Co-Founder, Chairman, CEO & President
    Comp: $851.61k
  • Dr. Enrique Poradosu Ph.D. (Age 57)
    Co-Founder, Executive VP, Chief Scientific & Business Officer
    Comp: $549.07k
  • Mr. Shay Shemesh (Age 40)
    Co-Founder, Executive VP, Chief Development & Operations Officer
    Comp: $529.27k
  • Mr. Michael Carson CPA (Age 47)
    Vice President of Finance

NVCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvectis Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVCT shares.
View NVCT analyst ratings
or view top-rated stocks.

What is Nuvectis Pharma's stock price target for 2024?

1 brokerages have issued twelve-month target prices for Nuvectis Pharma's shares. Their NVCT share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 215.3% from the stock's current price.
View analysts price targets for NVCT
or view top-rated stocks among Wall Street analysts.

How have NVCT shares performed in 2024?

Nuvectis Pharma's stock was trading at $8.34 at the beginning of the year. Since then, NVCT shares have decreased by 20.1% and is now trading at $6.66.
View the best growth stocks for 2024 here
.

When is Nuvectis Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NVCT earnings forecast
.

How were Nuvectis Pharma's earnings last quarter?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01.

When did Nuvectis Pharma IPO?

Nuvectis Pharma (NVCT) raised $19 million in an IPO on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.

How do I buy shares of Nuvectis Pharma?

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners